三种方案治疗椎-基底动脉供血不足的成本-效果分析  

Cost-effectiveness analysis of 3 different scheme for treating vertebrobasilar ischemia

作　　者：何伟[1] 刘华[2] 

机构地区：[1]武警辽宁总队医院药剂科,辽宁沈阳110034 [2]武警总医院药剂科,北京100039

出　　处：《武警医学院学报》2012年第3期182-183,共2页Acta Academiae Medicinae CPAPF

摘　　要：【目的】评价3种治疗椎-基底动脉供血不足的成本与效果。【方法】将我院符合标准的125例椎基底动脉供血不足的患者随机分为3组,A组(n=46)给与长春西汀注射液,B组(n=42)给予银杏叶提取物注射液,C组(n=37)给予血栓通冻干粉,用药物经济学方法给予分析。【结果】A、B、C三组的有效率分别为:91.3%、95.2%、78.4%;药物成本分别为:177.3元、324元、237元;成本-效果比分别为:1.94、3.40、3.02;B组、C组相对A组的增量成本—效果比分别为:37.62、-4.63。【结论】从药物经济学的角度,A方案为三种方案中治疗椎-基底动脉供血不足的最优方案。【Objective】To evaluate the economic effectiveness of 3 scheme for treating vertebrobasilar ischemid.【Methods】A total of 125 patients with clinical of vertebrobasilar insufficiency were divided into 3 group randomly.In group A Vinpocetina were given（therapy A n=46）,in group B extract of Ginkgo leaves injection given（therapy B n=42）and in group C（therapy C n=37）Sanqi Panax notoginseng given.【Results】The effective rates of group A,group B and group C were 91.3%,95.2% and 78.4% respectively,the costs were 177.3 yuan,324 yuan and 237 yuan respectively,the cost-effectiveness ratios were 1.94,3.40 and 3.02.The incremental cost-effectiveness ratios of group B and C group were 37.62 and-4.63.Compared with group A.【Conclusion】From the perspective of pharmacoeconomics,group A is optimal in the treatment of vertebrobasilar insufficiency among the three groups.

关 键 词：药物经济学 椎-基底动脉供血不足 成本-效果分析 

分 类 号：R774.1[医药卫生—眼科]